Status:

COMPLETED

Development of Non-invasive Prenatal Screening Test for Microdeletions Based on Fetal DNA Isolated From Maternal Blood

Lead Sponsor:

Natera, Inc.

Conditions:

Trisomy 21

Trisomy 18

Eligibility:

All Genders

18+ years

Brief Summary

The purpose of this study is to collect maternal blood samples from pregnant women carrying a fetus with a confirmed diagnosis of chromosomal abnormality or genetic disorder including microdeletions i...

Detailed Description

The goal of this study is to further develop a non-invasive prenatal blood test that can diagnose genetic disorders in the fetus by looking at fetal DNA (genetic material) found in the mother's bloods...

Eligibility Criteria

Inclusion

  • Age 18 or older at enrollment
  • Gestation age of at least 9 weeks, 0 days by best obstetrical estimate
  • One or more fetuses with a clinically confirmed diagnosis of a genetic variant of interest via karyotype, FISH, chromosomal microarray or other genetic assay AND/OR
  • One or more fetuses with any variant of fetal structure that is expected to require medical or surgical intervention in the newborn period, shorten lifespan, affect intellectual development or otherwise indicate a genetic anomaly AND/OR
  • Positive high risk noninvasive prenatal screening or serum screening result
  • Able to provide informed consent

Exclusion

  • •Maternal history of bone marrow or organ transplantation

Key Trial Info

Start Date :

November 1 2012

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

October 1 2020

Estimated Enrollment :

1059 Patients enrolled

Trial Details

Trial ID

NCT01852708

Start Date

November 1 2012

End Date

October 1 2020

Last Update

December 30 2020

Active Locations (9)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (9 locations)

1

Natera, Inc.

San Carlos, California, United States, 94070

2

MFM Group of Southern CA

San Gabriel, California, United States, 91776

3

Washington Women's Wellness Center

Washington D.C., District of Columbia, United States, 20010

4

Saint Peter's University Hospital

New Brunswick, New Jersey, United States, 08901

Development of Non-invasive Prenatal Screening Test for Microdeletions Based on Fetal DNA Isolated From Maternal Blood | DecenTrialz